CHRISTOPHER VAN HORN: Open Payments
NPI 1306825229 · LEAWOOD, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,202 in 133 payments from 18 companies in 2025. Trend: 2023 $1,512 · 2024 $2,001 · 2025 $2,202
Food & beverage: $2,202
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 23 | $364 |
| Vanda Pharmaceuticals Inc. | 13 | $319 |
| ABBVIE INC. | 22 | $276 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $255 |
| E.R. Squibb & Sons, L.L.C. | 14 | $181 |
| Neurocrine BioSciences, Inc. | 7 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $141 |
| Supernus Pharmaceuticals, Inc. | 5 | $99 |
| Lundbeck LLC | 4 | $98 |
| Almatica Pharma LLC | 4 | $78 |
Products named: REXULTI, VRAYLAR, HETLIOZ, CAPLYTA, COBENFY, ABILIFY ASIMTUFII, INGREZZA, TRINTELLIX.
Industry payments across KS — which companies pay providers there.
